中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

中草药相关肝损伤的研究进展与挑战

刘成海

引用本文:
Citation:

中草药相关肝损伤的研究进展与挑战

DOI: 10.12449/JCH240801
基金项目: 

上海市中医药事业发展三年行动计划 (ZY(2018-2020)-CCCX-5001);

上海市科学技术委员会科技创新行动计划医学创新研究专项 (20Z21900100);

上海市临床重点专科建设项目 (shslczdzk01201)

利益冲突声明:本文不存在任何利益冲突。
详细信息
    通信作者:

    刘成海, chenghailiu@hotmail.com (ORCID: 0000-0002-1696-6008)

Research advances and challenges in herb-induced liver injury

Research funding: 

Shanghai TCM Development Three-Year Action Plan Project (ZY(2018-2020)-CCCX-5001);

Shanghai Science and Technology Innovation Action Plan Medical Innovation Research Special Project (20Z21900100);

Shanghai Key Specialty of Traditional Chinese Clinical Medicine (shslczdzk01201)

More Information
  • 摘要: 中草药相关肝损伤发生众多,对中药临床安全用药与产业健康发展等有重要影响,近年来中草药肝损伤研究受到广泛重视并取得显著进展,我国与国际学术组织均制订并更新了相关临床诊疗指南。本文比较分析了近期有关中草药相关肝损伤诊疗指南的特点,继而从毒性机制、临床诊断与病情评估、风险因素与临床防治等方面简述主要进展,提出部分尚未满足的需求、需要重视的研究难点与可能的防治措施。

     

  • 表  1  国内外新近主要DILI诊疗指南关于HILI的比较

    Table  1.   Comparison of Chinese herbal medicine liver injury in the main DILI diagnosis and treatment guidelines

    项目 中华医学会肝病学分会 DILI指南(2023)6

    美国肝病学会

    DILI指南(2023)7

    亚太肝病学会 DILI指南(2021)8 CIOMS DILI共识(2020)9 欧洲肝病学会 DILI指南(2019)10
    TCM/HDS的 定义范围 中药及含有中药组分的保健食品,其中中药包括中药材、中药饮片、中药提取物、中药配方颗粒、中成药,民间用药材 HDS TCM、HDS HDS HDS
    占比 美国20%,欧洲和拉丁美洲8%~16%,中国20%~30%, 韩国27.5%,日本6%~9% HDS:20% 美国20%;中国20%~30%;西班牙13% HDS:美国20%,冰岛16%
    诊断 TCM/HDS肝毒性的诊断策略与DILI相同,根据TCM/HDS使用史、临床表现、体格检查、实验室检查、影像学或肝组织学检查等综合信息,排除其他肝损伤病因,最后诊断
    评估量表

    RUCAM评分,

    专家意见程序,

    证据链方法

    RUCAM评分,

    RECAM评分,

    CDS/DDW-J/SEOP,

    专家意见程序

    RUCAM评分,

    专家意见程序,

    证据链方法

    RUCAM评分,

    证据链方法

    RUCAM评分,

    CDS/SEOP,

    专家意见程序,

    证据链方法

    治疗 TCM/HDS肝损伤的治疗方案与DILI基本相同,包括停药、药物治疗等,进展至肝衰竭或肝功能失代偿可考虑人工肝支持,必要时行肝移植治疗

    注:TCM,中医药。

    下载: 导出CSV

    表  2  常见的导致肝损伤的中草药毒性成分和毒理机制

    Table  2.   The toxic components and mechanisms of common Chinese herbal medicine with liver toxicity

    药物 毒性成分 作用机制
    雷公藤 雷公藤甲素 ①脂质过氧化反应;②免疫性损伤;③P450酶系代谢异常;④肠道菌群
    黄药子 薯蓣皂苷及毒皂苷、呋喃去甲基二萜类化合物 ①肝细胞的氧化损伤直接毒性;②与胆汁淤积、胆盐刺激有关

    菊三七

    (土三七)

    吡咯烷类生物碱

    (千里光宁、千里光非灵和全缘千里光碱)

    代谢形成吡咯,与组织中的核酸与蛋白质等结合,或与还原型谷胱甘肽等形成加合物
    何首乌 蒽醌类 ①药物本身及代谢产物对肝细胞的直接毒性;②免疫性损伤
    千里光 吡咯里西啶类生物碱 代谢形成吡咯,与核酸或蛋白质等结合形成加合物,直接损伤肝窦内皮细胞,并导致肝窦阻塞
    苍耳子 苍术苷、毒蛋白 脂质过氧化反应
    薄荷 长叶薄荷酮、薄荷呋喃、异薄荷酮 炎症反应
    苍术 苍术苷、羧基或去磺基苍术苷 脂质过氧化反应、影响肝细胞能量代谢
    柴胡 柴胡总皂苷、柴胡皂苷D 氧化损伤
    淫羊藿 黄酮类(2″-鼠李糖基淫羊藿次苷Ⅱ、淫羊藿 次苷宝藿苷Ⅱ、淫羊藿素) ①氧化应激与细胞凋亡;②调控NLRP3炎症小体活性引起特异质性肝损伤;③抑制法尼醇X受体通路引起胆汁酸蓄积
    蓖麻子 蓖麻毒蛋白 与膜受体作用形成通道并内吞,催化失活核糖体的60S亚基,抑制蛋白质合成
    川楝子 呋喃三萜类化合物(川楝素) 降低线粒体膜电位,诱导肝细胞死亡
    大黄 大黄素、大黄蒽醌 肝细胞脂肪变性
    栀子 栀子苷 ①抑制CYP3A2活性,使毒性成分蓄积;②肝细胞脂质过氧化
    秋水仙 秋水仙碱 胆汁淤积
    麻黄 麻黄碱 脂质过氧化损伤
    山豆根 苦参碱 ①过氧化损伤;②脂质代谢紊乱;③炎症反应
    艾叶 艾叶挥发油 ①氧化应激;②线粒体结构与功能障碍
    补骨脂 补骨脂二氢黄酮甲醚 ①细胞凋亡与坏死;②脂质氧化应激损伤;③胆汁酸代谢与转运异常;④代谢酶活性抑制
    下载: 导出CSV
  • [1] SHEN T, LIU YX, SHANG J, et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019, 156( 8): 2230- 2241. e 11. DOI: 10.1053/j.gastro. 2019. 02.002.
    [2] ZHENG E, SANDHU N, NAVARRO V. Drug-induced liver injury secondary to herbal and dietary supplements[J]. Clin Liver Dis, 2020, 24( 1): 141- 155. DOI: 10.1016/j.cld.2019.09.009.
    [3] NAVARRO VJ, BARNHART H, BONKOVSKY HL, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network[J]. Hepatology, 2014, 60( 4): 1399- 1408. DOI: 10.1002/hep.27317.
    [4] VUPPALANCHI R, BONKOVSKY HL, AHMAD J, et al. Garcinia cambogia, either alone or in combination with green tea, causes moderate to severe liver injury[J]. Clin Gastroenterol Hepatol, 2022, 20( 6): e1416- e1425. DOI: 10.1016/j.cgh.2021.08.015.
    [5] JING J, WANG RL, ZHAO XY, et al. Association between the concurrence of pre-existing chronic liver disease and worse prognosis in patients with an herb-Polygonum multiflorum thunb. induced liver injury: A case-control study from a specialised liver disease center in China[J]. BMJ Open, 2019, 9( 1): e023567. DOI: 10.1136/bmjopen-2018-023567.
    [6] Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association; Study Group of Drug-Induced Liver Disease, Chinese Medical Association for the Study of Liver Diseases. Chinese guideline for diagnosis and management of drug-induced liver injury(2023 version)[J].[J]. Chin J Gastroenterol, 2023, 28( 7): 397- 431. DOI: 10.3760/cma.j.cn501113-20230419-00176.

    中国医药生物技术协会药物性肝损伤防治技术专业委员会, 中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版)[J]. 胃肠病学, 2023, 28( 7): 397- 431. DOI: 10.3760/cma.j.cn501113-20230419-00176.
    [7] FONTANA RJ, LIOU I, REUBEN A, et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury[J]. Hepatology, 2023, 77( 3): 1036- 1065. DOI: 10.1002/hep.32689.
    [8] DEVARBHAVI H, AITHAL G, TREEPRASERTSUK S, et al. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines[J]. Hepatol Int, 2021, 15( 2): 258- 282. DOI: 10.1007/s12072-021-10144-3.
    [9] Council for International Organizations of Medical Sciences. Drug-induced liver injury(DILI): Current status and future directions for drug development and the post-market setting[M]. Geneva, 2020.
    [10] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury[J]. J Hepatol, 2019, 70( 6): 1222- 1261. DOI: 10.1016/j.jhep. 2019. 02.014.
    [11] State Drug Administration. Technical guidelines for clinical evaluation of liver injury induced by traditional Chinese medicine[J]. J Clin Hepatol, 2018, 34( 7): 1403- 1409. DOI: 10.3969/j.issn.1001-5256.2018.07.008.

    国家药品监督管理局. 中药药源性肝损伤临床评价技术指导原则[J]. 临床肝胆病杂志, 2018, 34( 7): 1403- 1409. DOI: 10.3969/j.issn.1001-5256.2018.07.008.
    [12] World Health Organization. General guidelines for methodologies on research and evaluation of traditional medicine[M]. Geneva: World Health Organization, 2000.
    [13] YU YC, FAN Y, CHEN CW. Research status and prospect of liver injury related to herbs and dietary supplements[J]. Chin Hepatol, 2017, 22( 4): 296- 300. DOI: 10.14000/j.cnki.issn.1008-1704.2017.04.003.

    于乐成, 范晔, 陈成伟. 草药和膳食补充剂相关肝损伤的研究现状及展望[J]. 肝脏, 2017, 22( 4): 296- 300. DOI: 10.14000/j.cnki.issn.1008-1704.2017.04.003.
    [14] JING J, WANG RL, BAI ZF, et al. Interpretation on consensus on drug-induced liver injury by CIOMS Working Group: liver injury attributed to herbal and dietary supplements[J]. China J Chin Mater Med, 2023, 48( 9): 2552- 2556. DOI: 10.19540/j.cnki.cjcmm.20230123.501.

    景婧, 王睿林, 柏兆方, 等. CIOMS《药物性肝损伤国际共识》解读——草药和膳食补充剂(HDS)致肝损伤[J]. 中国中药杂志, 2023, 48( 9): 2552- 2556. DOI: 10.19540/j.cnki.cjcmm.20230123.501.
    [15] LIN N, JIANG Q, LIU W, et al. Editorial explanation for clinical practice guideline for Tripterygium Glycosides/Tripterygium wilfordii tablets in treatment of rheumatoid arthritis[J]. China J Chin Mater Med, 2020, 6( 17): 4154- 4157.

    林娜, 姜泉, 刘维, 等.《雷公藤多苷/雷公藤片治疗类风湿关节炎用药指南》编制说明[J]. 中国中药杂志, 2020, 6( 17): 4154- 4157.
    [16] GABBI C, BERTOLOTTI M. Drug-induced liver injury-types and phenotypes[J]. N Engl J Med, 2019, 381( 14): 1395- 1396. DOI: 10.1056/NEJMc1911063.
    [17] LI M, LI RR, LIU CH. Clinic diagnosis and treatment of herb-induced liver injury[J]. Chin J Pharmacovigil, 2023, 20( 2): 127- 131. DOI: 10.19803/j.1672-8629.20220661.

    李盟, 李容容, 刘成海. 中草药引起肝损伤的临床诊治与用药[J]. 中国药物警戒, 2023, 20( 2): 127- 131. DOI: 10.19803/j.1672-8629.20220661.
    [18] ARLT VM, STIBOROVA M, SCHMEISER HH. Aristolochic acid as a probable human cancer hazard in herbal remedies: A review[J]. Mutagenesis, 2002, 17( 4): 265- 277. DOI: 10.1093/mutage/17.4.265.
    [19] STIBOROVÁ M, FREI E, BREUER A, et al. Aristolactam I a metabolite of aristolochic acid I upon activation forms an adduct found in DNA of patients with Chinese herbs nephropathy[J]. Exp Toxicol Pathol, 1999, 51( 4-5): 421- 427. DOI: 10.1016/S0940-2993(99)80033-5.
    [20] JIANG HY, BAO YN, LIN FM, et al. Triptolide regulates oxidative stress and inflammation leading to hepatotoxicity via inducing CYP2E1[J]. Hum Exp Toxicol, 2021, 40( 12_suppl): S775- S787. DOI: 10.1177/09603271211056330.
    [21] LI J, SHEN FH, GUAN CW, et al. Activation of Nrf2 protects against triptolide-induced hepatotoxicity[J]. PLoS One, 2014, 9( 7): e100685. DOI: 10.1371/journal.pone.0100685.
    [22] LI CP, RAO T, CHEN XP, et al. HLA-B*35:01 allele is a potential biomarker for predicting Polygonum multiflorum-induced liver injury in humans[J]. Hepatology, 2019, 70( 1): 346- 357. DOI: 10.1002/hep.30660.
    [23] REMASH D, PRINCE DS, MCKENZIE C, et al. Immune checkpoint inhibitor-related hepatotoxicity: A review[J]. World J Gastroenterol, 2021, 27( 32): 5376- 5391. DOI: 10.3748/wjg.v27.i32.5376.
    [24] LI M, LUO Q, CHEN X, et al. Screening of major hepatotoxic components of Tripterygium wilfordii based on hepatotoxic injury patterns[J]. BMC Complement Med Ther, 2023, 23( 1): 9. DOI: 10.1186/s12906-023-03836-w.
    [25] MU GD, NIU M, GAO YJ, et al. Construction and application of liver injury risk prediction model of Chinese medicinals based on indirect toxicity[J]. J Tradit Chin Med, 2023, 64( 17): 1763- 1770. DOI: 10.13288/j.11-2166/r.2023.17.008.

    母光頔, 牛明, 高云娟, 等. 基于间接毒性认知的中药肝损伤风险预测模式的构建及应用[J]. 中医杂志, 2023, 64( 17): 1763- 1770. DOI: 10.13288/j.11-2166/r.2023.17.008.
    [26] WANG XY, LI WX, ZHANG H, et al. The mechanism of Psoralea fructus induced idiosyncratic liver injury based on metabolomics[J]. Chin J Pharmacovigil, 2021, 18( 11): 1014- 1019. DOI: 10.19803/j.1672-8629.2021.11.04.

    王晓艳, 李伟霞, 张辉, 等. 基于代谢组学的补骨脂致特异质肝损伤机制研究[J]. 中国药物警戒, 2021, 18( 11): 1014- 1019. DOI: 10.19803/j.1672-8629.2021.11.04.
    [27] MA J, XIA QS, FU PP, et al. Pyrrole-protein adducts-A biomarker of pyrrolizidine alkaloid-induced hepatotoxicity[J]. J Food Drug Anal, 2018, 26( 3): 965- 972. DOI: 10.1016/j.jfda.2018.05.005.
    [28] XU ZN, ZHAO YQ, CHEN SY, et al. Advantage and risk analysis on combination of traditional Chinese medicines and Western medicines[J]. Chin Tradit Herb Drugs, 2023, 54( 2): 408- 415. DOI: 10.7501/j.issn.0253-2670.2023.02.007.

    徐振娜, 赵逸卿, 陈思宇, 等. 中西药联合用药的优势及风险分析[J]. 中草药, 2023, 54( 2): 408- 415. DOI: 10.7501/j.issn.0253-2670.2023.02.007.
    [29] DING ZH, ZHANG YQ, LIN N. Component-effect/toxicity-target correlations of Tripterygium wilfordii in terms of lipid metabolism[J]. Chin J Pharmacovigil, 2023, 20( 5): 489- 495. DOI: 10.19803/j.1672-8629.20220734.

    丁子禾, 张彦琼, 林娜. 从脂质代谢途径探讨中药雷公藤“物-效/毒-靶”关联性的研究现状与展望[J]. 中国药物警戒, 2023, 20( 5): 489- 495. DOI: 10.19803/j.1672-8629. 20220734.
    [30] HUANG JF, ZHAO Q, DAI MY, et al. Gut microbiota protects from triptolide-induced hepatotoxicity: Key role of propionate and its downstream signalling events[J]. Pharmacol Res, 2020, 155: 104752. DOI: 10.1016/j.phrs.2020.104752.
    [31] BAI ZF, ZHAN XY, YAO Q, et al. Theoretical innovation and technological breakthroughs in the safety evaluation of traditional Chinese medicine: Disease-syndrome-based toxicology[J]. Chin J Pharmacovigil, 2024, 21( 1): 6- 14. DOI: 10.19803/j.1672-8629.20230787.

    柏兆方, 湛小燕, 姚清, 等. 中药安全性评价理论创新与技术突破:病证毒理学[J]. 中国药物警戒, 2024, 21( 1): 6- 14. DOI: 10.19803/j.1672-8629.20230787.
    [32] HE TT, GONG M, BAI YF, et al. Clinical analysis of two diagnosis methods for herb-induced liver injury[J]. China J Chin Mater Med, 2016, 41( 16): 3096- 3099. DOI: 10.4268/cjcmm20161626.

    何婷婷, 宫嫚, 白云峰, 等. 2种药物性肝损伤诊断指南的应用分析[J]. 中国中药杂志, 2016, 41( 16): 3096- 3099. DOI: 10.4268/cjcmm20161626.
    [33] MENG Y, ZHANG MM, ZHAO XY. Evolution of causality evaluation of drug-induced liver injury: From RUCAM to RECAM[J]. Chin Hepatol, 2023, 28( 6): 631- 633. DOI: 10.14000/j.cnki.issn.1008-1704.2023.06.001.

    孟尧, 张萌萌, 赵新颜. 药物性肝损伤因果关系评估演变:从RUCAM到RECAM[J]. 肝脏, 2023, 28( 6): 631- 633. DOI: 10.14000/j.cnki.issn.1008-1704.2023.06.001.
    [34] AHMAD J, BARNHART HX, BONACINI M, et al. Value of liver biopsy in the diagnosis of drug-induced liver injury[J]. J Hepatol. 2022, 76( 5): 1070- 1078. DOI: 10.1016/j.jhep.2021.12.043.
    [35] LUO Q, ZHU GR, GU HT, et al. Liver histopathological features of patients with drug-induced liver injury due to Chinese herbal medicine or Western medicine: A comparative analysis of 50 cases[J]. J Clin Hepatol, 2020, 36( 3): 596- 601. DOI: 10.3969/j.issn.1001-5256.2020.03.025.

    罗琼, 朱哿瑞, 顾宏图, 等. 50例中草药与西药致药物性肝损伤患者的肝组织病理学特点比较[J]. 临床肝胆病杂志, 2020, 36( 3): 596- 601. DOI: 10.3969/j.issn.1001- 5256. 2020. 03.025.
    [36] Cooperative Group for Hepatic and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association. Expert consensus on diagnosis and treatment of pyrrolidine alkaloids-related sinusoidal obstruction syndrome(2017, Nanjing)[J]. J Clin Hepatol, 2017, 3( 9): 1627- 1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003.

    中华医学会消化病学分会肝胆疾病协作组. 吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年, 南京)[J]. 临床肝胆病杂志, 2017, 33( 9): 1627- 1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003.
    [37] LIU CH, ZHU CW. Epidemic features, major causes, and diagnostic evaluation of herb-induced liver injury[J]. J Clin Hepatol, 2017, 33( 5): 829- 832. DOI: 10.3969/j.issn.1001-5256.2017.05.007.

    刘成海, 朱春雾. 中草药相关药物性肝损伤的流行特点、主要原因与诊断评估[J]. 临床肝胆病杂志, 2017, 33( 5): 829- 832. DOI: 10.3969/j.issn.1001-5256.2017.05.007.
    [38] World Health Organization. Key technical issues of herbal medicines with reference to interaction with other medicines[M]. Geneva: World Health Organization, 2021.
    [39] WANG LX, WANG MM, LI YY, et al. Pharmacovigilance Guidelines for proprietary Chinese medicines[J/OL]. Chin J Chin Mat Med, 2024: 1- 7.[ 2024-07-10]. https://doi.org/10.19540/j.cnki.cjcmm.20240623.501. DOI: 10.19540/j.cnki.cjcmm.20240623.501

    王连心, 王萌萌, 黎元元, 等. 中成药药物警戒指南[J/OL]. 中国中药杂志, 2024: 1- 7.[ 2024-07-10]. https://doi.org/10.19540/j.cnki.cjcmm.20240623.501. DOI: 10.19540/j.cnki.cjcmm.20240623.501
    [40] SONG HB, HAN L. Epidemiologic characteristics, risk factors and safety evaluation of traditional Chinese medicine induced liver injury[J]. Chin J Pharmacol Toxicol, 2016, 30( 4): 291- 305. DOI: 10.3867/j.issn.1000-3002.2016.04.001.

    宋海波, 韩玲. 中药肝损伤的流行特点、风险因素及评价[J]. 中国药理学与毒理学杂志, 2016, 30( 4): 291- 305. DOI: 10.3867/j.issn.1000-3002.2016.04.001.
    [41] HOOFNAGLE JH, BONKOVSKY HL, PHILLIPS EJ, et al. HLA-B*35:01 and green tea-induced liver injury[J]. Hepatology, 2021, 73( 6): 2484- 2493. DOI: 10.1002/hep.31538.
  • 加载中
表(2)
计量
  • 文章访问数:  540
  • HTML全文浏览量:  487
  • PDF下载量:  162
  • 被引次数: 0
出版历程
  • 收稿日期:  2024-06-26
  • 录用日期:  2024-07-10
  • 出版日期:  2024-08-25
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回